About

About Ocular Therapeutix Inc About Ocular Therapeutix Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience across development, treatment, and outcomes. OTX-TKI (also known as AXPAXLI™), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based technology. It is currently in Phase 3 clinical trials to advance wet age-related macular degeneration (AMD) and diabetic retinopathy (DR) treatment, aiming to improve long-term outcomes while reducing the frequency of injections. Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions.